Highest-materiality recent filing
Pacira Q2 revenue $192.4M (+6% YoY); divests iovera° to Zimmer Biomet for up to $140M
Q2 total revenue $192.4M (+6% YoY); GAAP net income $4.7M ($0.12 EPS) vs net loss of $4.8M in Q2 2025.
Pacira divests iovera business to Zimmer Biomet for up to $140M
Upfront payment of $70M; potential milestone payments up to $70M through 2031.
Pacira stockholders elect all three company director nominees; 2011 stock incentive plan fails
All three company nominees (Christie, Hirawat, Wiggans) elected with ~25-28M votes; dissident slate from DOMA defeated with ~4.6M votes.
Pacira Q1 revenue $177M (+5% YoY); GAAP EPS $0.07, non-GAAP $0.60; FY guidance reiterated
Total revenue $177.4M (+5% YoY); EXPAREL $143.3M (+5%), ZILRETTA $26.8M (+15%), iovera° $6.2M (+21%).
Pacira BioSciences reports Q4 2025 revenue of $196.9M, up 5%, and full-year 2026 guidance
Q4 2025 total revenue $196.9M (5% increase vs Q4 2024); EXPAREL sales $155.8M (+5%)
Pacira reports preliminary 2025 revenue of $726.4M; EXPAREL sales record high with 7% volume growth
Total revenue $726.4M vs $701.0M in FY2024, up 3.6%.
Total revenues $179.5M, up 6% YoY; EXPAREL $139.9M (volume +9% offset by mix and discounting).
Pacira Q2 2025 revenue $181.1M, GAAP net loss $4.8M; guidance updated, legal win $28.3M
Total revenues $181.1M (+2% YoY); EXPAREL $142.9M, ZILRETTA $31.3M, iovera° $5.6M.
Pacira BioSciences cuts 71 jobs (8% of workforce); decommissions 45-liter EXPAREL suite in San Diego
Workforce reduction of 71 employees (~8% of total) from Technical Operations at San Diego Science Center Campus.
Pacira shareholders approve 2.5M share increase to equity plan; say-on-pay fails
Stockholders approved Amended 2011 Plan adding 2,500,000 new shares for future grants.
Pacira Q1 revenue $168.9M, net income $4.8M; EXPAREL exclusivity extended to 2039
Total revenues $168.9M (+1% YoY); GAAP net income $4.8M ($0.10) vs $9.0M ($0.19) a year ago.
Pacira Biosciences authorizes $300M share repurchase program through Dec 31, 2026
Board approved $300M stock buyback, effective immediately, replacing the May 7, 2024 program.
Pacira settles EXPAREL patent litigation; Fresenius licensed to sell generic from early 2030
Settlement with Fresenius Kabi, eVenus, Jiangsu Hengrui resolves all patent suits over EXPAREL (bupivacaine liposome).
Q4 2024 rev $187.3M (+3% YoY); full-year rev $701.0M (+4%); EXPAREL $549M, ZILRETTA $118M, iovera $22.8M.
Pacira BioSciences appoints Laura Brege as Board Chair; two directors retire
Paul J. Hastings (former Chair) and Andreas Wicki retired effective Jan. 28, 2025; no disagreement cited.
Pacira appoints Brendan Teehan as CCO, Krys Corbett as CBO; adds 785K shares to inducement plan
Brendan Teehan named Chief Commercial Officer effective Jan 21, 2025; previously COO at Acadia Pharmaceuticals.
Pacira preliminary FY2024 revenue $701M (+3.9% YoY); announces 5x30 growth plan
FY2024 total revenue of $701.0M, up from $675.0M in 2023; Q4 EXPAREL $147.7M.
Pacira Q3 revenue $168.6M, net loss $143.5M on $163.2M goodwill impairment; affirms FY guidance
Revenue $168.6M; EXPAREL $132.0M (+2.6%), ZILRETTA $28.4M, iovera° $5.7M.
Pacira BioSciences appoints Shawn Cross as CFO effective Oct 21, 2024
Shawn Cross appointed CFO effective Oct 21, 2024; succeeds interim CFO Lauren Riker, who remains SVP of Finance.
Pacira names Lauren Riker interim CFO; Reinhart departs Sept 30
CFO Charles Reinhart departs Sept 30, 2024; will serve as consultant for 9 months.
Pacira's EXPAREL patent invalidated by New Jersey court; company plans appeal
U.S. District Court for D.N.J. ruled Pacira's U.S. Patent No. 11,033,495 for EXPAREL is invalid.
Total revenues of $178.0M, up 5% YoY; EXPAREL sales $136.9M (+1.3%), ZILRETTA $30.7M.
Pacira BioSciences issues $287.5M convertible notes, repurchases $200M of 2025 notes and $25M stock
Issued $250.0M (plus $37.5M option) of 2.125% Convertible Senior Notes due 2029; net proceeds ~$278.4M.
Pacira proposes $250M convertible note offering due 2029; up to $50M share repurchase
Proposed offering of $250M aggregate principal of Convertible Senior Notes due 2029, with initial purchasers' option for additional $37.5M.
Pacira Q1 net income $9.0M ($0.19 EPS); announces $150M share repurchase
GAAP net income $9.0M ($0.19/sh) vs net loss $19.5M ($0.43 loss) YoY.
Pacira BioSciences: FY2023 revenue $675M (+1% YoY), net income $42M; CFO to leave Sept 30
Q4 revenue $181.2M (+5% YoY), GAAP net income $24.9M ($0.54 basic EPS), adj EBITDA $65.4M.
Pacira reports preliminary FY2023 revenue of $675.0M, up 1.2% YoY; Q4 EXPAREL sales $143.9M
FY2023 total revenue $675.0M vs $666.8M in FY2022, driven by EXPAREL ($538.1M), ZILRETTA ($111.1M), iovera° ($19.7M).
Pacira appoints Frank D. Lee as CEO effective Jan 2, 2024; Stack retires to advisory role
Frank Lee named CEO and Board member, effective Jan 2, 2024; prior CEO of Forma Therapeutics.
Pacira Q3 net income $10.9M, cuts FY EXPAREL guidance; CEO Stack to retire
Total revenues $163.9M, down ~2% YoY; EXPAREL sales $128.7M, down from $132.6M.
Pacira CEO David Stack to retire; board initiates search for successor
Stack will remain as CEO until successor is appointed, then serve as consultant through August 2025.
Pacira Q2 net income $25.8M; EXPAREL guidance cut to $550-560M
Total revenue $169.5M flat YoY; EXPAREL net sales $135.1M down from $137.0M.
Pacira Q1 total revenue $160.3M; net loss $19.5M; EXPAREL sales $130.4M
Total revenues $160.3M vs $158.0M in Q1 2022, up 1.5%; GAAP net loss $0.43/share vs net income $0.15/share.
Repaid $287.5M Term Loan B outstanding using $150M new Term Loan A and cash on hand.
Pacira BioSciences reports record 2022 revenue of $667M; Q4 GAAP net loss widens to $10.1M
Full-year 2022 revenue $666.8M (+23% YoY); GAAP net income $15.9M ($0.34 diluted EPS) vs $42.0M ($0.92) in 2021.
Pacira BioSciences reports preliminary 2022 revenue of $666.8M, up 23.1% YoY
EXPAREL net sales $536.9M in 2022 vs $506.5M in 2021; Q4 2022 sales $138.0M, roughly flat vs prior Q4.
Pacira Q3 revenue up 31% to $167.5M, GAAP net loss $0.7M; EXPAREL sales $132.6M, patent to 2041
Total revenues $167.5M (+31% YoY); EXPAREL $132.6M (+9%), ZILRETTA $26.5M.
Pacira reports preliminary Q3 2022 revenue of $167.5M, up 31% YoY; EXPAREL sales up 9%
Preliminary unaudited Q3 2022 revenue $167.5M vs $127.7M in Q3 2021.
On January 28, 2025, Paul J. Hastings, Chair of the Board of Directors (the “Board”), and Andreas Wicki, a member of the Board, each notified the Board of Pacira BioSciences, Inc. (the “Company”) of his respective decision to resign as a member of the Board, in each case, effective immediately
On January 28, 2025, Paul J. Hastings, Chair of the Board of Directors (the “Board”), and Andreas Wicki, a member of the Board, each notified the Board of Pacira BioSciences, Inc. (the “Company”) of his respective decision to resign as a member of the Board, in each case, effective immediately
the Board, upon recommendation of the Nominating, Governance and Sustainability Committee of the Board, appointed Laura Brege as Chair of the Board, effective as of immediately following the effectiveness of the Resignations.
On January 16, 2025, Brendan Teehan was appointed Chief Commercial Officer of Pacira BioSciences, Inc. (the “Company”), effective January 21, 2025.
On January 16, 2025, Daryl Gaugler was named Executive Vice President, Commercial Operations, instead of his former title as Chief Operating Officer.
Mr. Cross will succeed Lauren Riker, who had been serving as interim Chief Financial Officer since October 1, 2024.
appointed Shawn M. Cross to serve as the Chief Financial Officer of the Company, effective October 21, 2024.
Charles A. Reinhart, III, the Company’s Chief Financial Officer, agreed that he would depart the Company effective September 30, 2024, and will continue to serve as consultant to the Company for a period of nine months thereafter.
On September 26, 2024, the Board of Directors of the Company (the “Board”) appointed Lauren Riker, the Company’s current Senior Vice President of Finance and principal accounting officer, to also serve as interim Chief Financial Officer of the Company (including as principal financial officer and continuing as principal accounting officer for Securities and Exchange Commission reporting purposes), effective October 1, 2024.
On June 11, 2024, Gary Pace notified the Board of Directors (the “Board”) of Pacira BioSciences, Inc. (the “Company”) of his intent to retire from the Board, effective June 30, 2024.
On February 26, 2024, the Company and Charles A. Reinhart, III, the Company’s Chief Financial Officer, agreed that he will depart the Company, effective September 30, 2024 (the “Transition Date”).
David Stack informed the Board of Directors (the "Board") of Pacira BioSciences, Inc. (the "Company") that he intended to retire as Chief Executive Officer of the Company and as a member of the Board effective immediately following the appointment of his successor as Chief Executive Officer.
Max materiality 0.90 · Median 0.70 · Most common event earnings